Sign in

Private company

eFFECTOR Therapeutics, Inc.

EFFECTOR Therapeutics, Inc. is an American pharmaceutical preparations company based in San Diego.2

Last updated Oct 21, 2026.

Overview

  • IndustryPharmaceutical Preparations2
  • HeadquartersSan Diego, United States2
  • Incorporated inDE3
  • Business address142 North Cedros Avenue, Suite B, Solana Beach, Ca 920753
  • Filer category, Emerging growth company3
  • Legal formCorporation2
  • LEI5493006L4NK7W3Z334152
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressC/O The Corporation Trust Company, 19801 Wilmington, United States2
  • Registered withDivision of Corporations, Department of State, 51453232

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2023

-100.0%Revenue growth, 20234

Financial statements

Revenue564$0 in 2023
0$20.0M$40.0M$60.0M2020: $42.0M$42.0M20202021: $1.4M$1.4M2021−97%2022: $3.6M$3.6M2022+148%2023: $0$02023
Operating income564-$33.8M in 2023
-$40.0M-$20.0M0$20.0M2020: $15.8M$15.8M20202021: -$31.9M-$31.9M20212022: -$32.4M-$32.4M2022+2%2023: -$33.8M-$33.8M2023+4%
Net income564-$35.8M in 2023
-$40.0M-$20.0M0$20.0M2020: $14.2M$14.2M20202021: $15.8M$15.8M2021+11%2022: -$22.7M-$22.7M20222023: -$35.8M-$35.8M2023+58%
Fiscal year20192020202120222023
Revenue$42.0M5$1.4M6$3.6M4$04
Research and development$21.8M5$20.0M6$23.3M4$22.9M4
Operating expenses$33.3M6$36.0M4$33.8M4
Operating income$15.8M5-$31.9M6-$32.4M4-$33.8M4
Interest$1.3M5$1.8M6$2.3M4$2.9M4
Income before tax$15.8M5
Income tax$351.0K5$06$04$04
Net income$14.2M5$15.8M6-$22.7M4-$35.8M4
Earnings per share$0.125$1.056-$13.764-$16.374
Earnings per share (diluted)$0.115$0.446-$13.764-$16.374
Shares (weighted, basic)15.1M shares61.6M shares42.2M shares4
Shares (weighted, diluted)36.0M shares61.6M shares42.2M shares4

Compare eFFECTOR Therapeutics, Inc. with another company

Corporate structure

eFFECTOR Therapeutics, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of eFFECTOR Therapeutics, Inc.

  • eFFECTOR Therapeutics, Inc. San Diego, California, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What eFFECTOR Therapeutics, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$464.0K4 Dec 31, 2023$457.0K4 Dec 31, 2022+1.5%
Accumulated depreciation$324.0K4 Dec 31, 2023$216.0K4 Dec 31, 2022+50.0%
Property and equipment, net$140.0K4 Dec 31, 2023$241.0K4 Dec 31, 2022−41.9%
Operating-lease assets (leased space)$53.0K4 Dec 31, 2023$111.0K4 Dec 31, 2022−52.3%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$14.9M4 Dec 31, 2023$8.7M4 Dec 31, 2022+70.8%
Marketable securities, current$3.5M4 Dec 31, 2023$17.6M4 Dec 31, 2022−80.1%

Leadership

Who has led eFFECTOR Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Christopher B. Ehrlich2021
  2. Stephen T. Worland2021–2024

President

  1. Stephen T. Worland2021–2022

Chief financial officer

  1. Daniel E. Geffken2021
2025
Board members and other officers (17)

Former names

  • Locust Walk Acquisition Corp.Nov 4, 2020 to Aug 25, 20213

Timeline

  1. Jun 26, 20248-K Debt or obligation accelerated28
  2. Jun 25, 20248-K Listing notice or transfer29
  3. Jun 24, 20248-K Exit or restructuring costs; Executive or director change; Other events30
  4. Jun 14, 20248-K Bylaws or fiscal year changed; Shareholder vote31
  5. May 20, 20248-K Other events32
  6. May 17, 20248-K Listing notice or transfer33
  7. May 9, 20248-K Listing notice or transfer; Change in control34
  8. May 9, 20248-K Results of operations35
  9. May 9, 20248-K Entered a material agreement; Ended a material agreement36
  10. Apr 4, 20248-K Other events37
  11. Mar 25, 20248-K Results of operations38
  12. Jan 30, 20248-K Other events39
  13. Aug 27, 2021New chief executive Stephen T. Worland becomes CEO11
  14. Jan 7, 2021New chief executive Christopher B. Ehrlich becomes CEO10
  15. May 1, 2012Founded eFFECTOR Therapeutics, Inc. is founded2

Calendar

When it reported results

  1. May 9, 2024Reported quarterly or annual results35
  2. Mar 25, 2024Reported quarterly or annual results38
  3. Jan 8, 2024Reported quarterly or annual results40
  4. Nov 13, 2023Reported quarterly or annual results41
  5. Aug 8, 2023Reported quarterly or annual results42
  6. May 9, 2023Reported quarterly or annual results43
  7. Mar 8, 2023Reported quarterly or annual results44
  8. Nov 7, 2022Reported quarterly or annual results45

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

286 filings to the SEC since October 2021: 3 annual reports, 8 quarterly reports, 50 major events, 104 insider forms, 19 large holders, 102 other. The latest 20:

  1. Aug 1, 2024EFFECT EDGAR
  2. Aug 1, 2024EFFECT EDGAR
  3. Aug 1, 2024EFFECT EDGAR
  4. Aug 1, 2024EFFECT EDGAR
  5. Jul 30, 202415-12G EDGAR
  6. Jul 30, 2024S-8 POS EDGAR
  7. Jul 30, 2024S-8 POS EDGAR
  8. Jul 30, 2024POS AM EDGAR
  9. Jul 30, 2024POS AM EDGAR
  10. Jul 30, 2024POS AM EDGAR
  11. Jul 30, 2024POS AM EDGAR
  12. Jun 26, 20248-K EDGAR
  13. Jun 25, 20248-K EDGAR
  14. Jun 24, 20248-K EDGAR
  15. Jun 14, 20248-K EDGAR
  16. Jun 13, 20244 EDGAR
  17. Jun 13, 20244 EDGAR
  18. Jun 13, 20244 EDGAR
  19. Jun 13, 20244 EDGAR
  20. Jun 13, 20244 EDGAR

The 286 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

69 open-market trades by officers, directors and large owners since October 2021: 12 buys and 57 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Nov 27, 2023SR One Co-Invest I, LLC10% ownerSale609,163$0.61$371.6KForm 4
Oct 4, 2022Ehrlich Christopher BDirectorBuy346$0.57$197Form 4
Sep 26, 2022Ehrlich Christopher BDirectorBuy18,867$0.55$10.4KForm 4
Aug 3, 2022Tansey Casey M10% ownerSale59,376$0.80$47.5KForm 4
Aug 2, 2022Tansey Casey M10% ownerSale28,201$0.80$22.6KForm 4
Aug 1, 2022Tansey Casey M10% ownerSale26,703$0.79$21.1KForm 4
Jul 28, 2022Tansey Casey M10% ownerSale32,517$0.89$28.9KForm 4
Jul 27, 2022ROOT JONATHAN D10% ownerSale43,665$0.89$38.9KForm 4
Jul 26, 2022ROOT JONATHAN D10% ownerSale2,775$0.90$2.5KForm 4
Jul 25, 2022ROOT JONATHAN D10% ownerSale2,279$0.93$2.1KForm 4
Jul 22, 2022US VENTURE PARTNERS X LP10% ownerSale7,614$0.91$6.9KForm 4
Jul 21, 2022US VENTURE PARTNERS X LP10% ownerSale2,665$0.96$2.6KForm 4
Jul 20, 2022US VENTURE PARTNERS X LP10% ownerSale10,030$1.00$10.0KForm 4
Jul 19, 2022US VENTURE PARTNERS X LP10% ownerSale2,754$1.00$2.8KForm 4
Jul 18, 2022US VENTURE PARTNERS X LP10% ownerSale20,987$1.08$22.7KForm 4
Jul 15, 2022US VENTURE PARTNERS X LP10% ownerSale45,900$1.11$50.9KForm 4
Jun 23, 2022Gallagher Brian M. Jr.DirectorBuy30,000$1.59$47.7KForm 4
Jun 7, 2022WORLAND STEPHEN TChief Executive OfficerBuy20,000$1.37$27.4KForm 4
Jun 7, 2022Byrnes MichaelChief Financial OfficerBuy25,000$1.33$33.2KForm 4
May 19, 2022Tansey Casey M10% ownerSale8,574$1.69$14.5KForm 4

All 69 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How eFFECTOR Therapeutics, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGAReFFECTOR Therapeutics, Inc.1
  • CIK0001828522
  • Employer ID (EIN)85-33063961
  • Filer status<br>emerging growth company1
  • Incorporated inDelaware1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address142 North Cedros Avenue, Suite B, Solana Beach, CA 920751
  • Phone(858) 925-82151
  • Shares outstanding4,704,409 as of Apr 30, 20249
  • Public float$51.3M as of Jun 30, 20234
  • On EDGAR sinceNov 4, 20201
  • Filings381 in all: 4 (115), 8-K (56), 424B3 (49), 3 (26), EFFECT (15), 10-Q (10), CORRESP (10), 425 (9)1
    All 38 form types

    POS AM (9), SC 13G/A (9), SC 13G (8), SC 13D/A (7), UPLOAD (7), 424B5 (6), 10-K (4), DEF 14A (3), DEFA14A (3), S-1 (3), S-4/A (3), SC 13D (3), 25-NSE (2), 8-K/A (2), ARS (2), PRE 14A (2), S-3 (2), S-8 (2), S-8 POS (2), SEC STAFF LETTER (2), 15-12G (1), 4/A (1), 424B4 (1), 8-A12B (1), CERT (1), DRS (1), NT 10-Q (1), S-1/A (1), S-1MEF (1), S-4 (1)

  • Latest filingsAnnual report (10-K) Mar 26, 2024
    Quarterly report (10-Q) May 9, 2024
    Proxy statement (DEF 14A) Apr 26, 2024
    Latest 8-K (8-K) Jun 26, 2024

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
    SEC EDGAROther events
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
    SEC EDGAROther events
  38. 38
  39. 39
    SEC EDGAROther events
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55